Janus Kinase Inhibitors against Other Biological Treatments in Alopecia Areata

Tavakolpour, Soheil

doi:10.1111/sji.12423

Cited by 6 publications

(5 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In patients with advancing AA, changes in the activation state of peripheral blood mononuclear cells and upregulation of the co‐stimulatory molecules CD40 and CD80, the accessory molecule CD154, and interferon γ expression were identified and were independent of the extent of hair loss (Tavakolpour, ).…”

Section: Introductionmentioning

confidence: 99%

Treatment of chronic extensive alopecia areata by diphenylcyclopropenone alone versus in combination with anthralin

Ibrahim

Esawy

Abdelshafy

2019

Dermatologic Therapy

View full text Add to dashboard Cite

Alopecia areata (AA) is a chronic inflammatory, recurrent, tissue‐specific autoimmune disease, mediated by autoreactive CD8+ T cells, occurring in genetically predisposed individuals. Targeting intrabulbar and peribulbar lymphocytic infiltrate by using squaric acid dibutyl ester and diphenylcyclopropenone (DPCP) in contact immunotherapy is by far the best chemotherapy for AA. The aim of this work was to evaluate the efficacy and safety of combination therapy with DPCP and anthralin in chronic extensive AA. A total of 24 patients (12 were treated only with DPCP and 12 with DPCP and anthralin for at least 24 weeks) were evaluated. Complete hair regrowth was observed in 62.5 and 18.2% of the patients who received DPCP and combination therapy, respectively (p = .04). Hair regrowth duration was different in both groups. The DPCP therapy is superior to the combination therapy with DPCP and anthralin in terms of efficacy, the time of onset of hair regrowth, and the time of completion of hair regrowth, Moreover, combination therapy has more side effects in combination therapy group have been discussed in this work.

show abstract

Section: Introductionmentioning

confidence: 99%

Treatment of chronic extensive alopecia areata by diphenylcyclopropenone alone versus in combination with anthralin

Ibrahim

Esawy

Abdelshafy

2019

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

“…For example, alopecia areata (AA) has been previously identified as a Th1/T17‐dominant disease. However, the author has hypothesized that CD8 + T cells are possibly responsible for (AA), and Th1/Th17 may not be main players .…”

Section: Autoimmune Diseases and Pregnancymentioning

confidence: 99%

New Insights into the Management of Patients with Autoimmune Diseases or Inflammatory Disorders During Pregnancy

Tavakolpour

Rahimzadeh

2016

Scand J Immunol

View full text Add to dashboard Cite

The treatment of autoimmune diseases remains a serious problem. Current therapies can lead to adverse effects in patients. One of the most vulnerable patient groups is pregnant women. It has been reported that different autoimmune diseases have a certain trend during pregnancy and after delivery which could be explained by maternal immune responses. Better management of pregnant women with autoimmune diseases or inflammatory disorders could be achieved by linking such alterations in immune responses and governed immune responses in different autoimmune disorders while considering various reports of autoimmune conditions during pregnancy. This study considers changing the T helper cells (Th1) and Th2 balance and suggests some new approaches for the better management of autoimmune diseases in pregnant women based on immune responses. Additionally, the possible role of Th17, alterations in some selected autoimmune diseases including rheumatoid arthritis (RA), multiple sclerosis (MS), psoriasis, systemic lupus erythematosus (SLE), atopic dermatitis (AD), asthma and pemphigus during pregnancy, and possible associated mechanisms are discussed.

show abstract

“…In this disease, due to aggressive and aberrant immune responses of different subtypes of effector T cells (T effs ) and also tenuous regulatory T cells (T regs ) responses, it seems that development of AA is strongly associated with the low number and/or dysfunction of T regs alongside increase in aberrant immune responses, which have been recently discussed as the novel therapeutic options of AA Tavakolpour, 2016). In this disease, due to aggressive and aberrant immune responses of different subtypes of effector T cells (T effs ) and also tenuous regulatory T cells (T regs ) responses, it seems that development of AA is strongly associated with the low number and/or dysfunction of T regs alongside increase in aberrant immune responses, which have been recently discussed as the novel therapeutic options of AA Tavakolpour, 2016).…”

mentioning

confidence: 99%

“…The first step is to recognize the genes involved in AA, which seem to be inhibited during AA disease. In this disease, due to aggressive and aberrant immune responses of different subtypes of effector T cells (T effs ) and also tenuous regulatory T cells (T regs ) responses, it seems that development of AA is strongly associated with the low number and/or dysfunction of T regs alongside increase in aberrant immune responses, which have been recently discussed as the novel therapeutic options of AA Tavakolpour, 2016). Thus, we should seek for T regs -associated genes, like T regs transcription factor, forkhead box p3 (FOXP3) in addition to co-inhibitory molecules, including cytotoxic T-lymphocyteassociated protein 4 (CTLA-4), B-and T-lymphocyte attenuator (BTLA), programmed cell death protein 1 (PD-1), T-cell immunoglobulin, and mucin-domain containing-3 (TIM-3), CD160, lymphocyte activation gene-3 (LAG-3), and leukocyte-associated immunoglobulin-like receptor 1 (LAIR1).…”

mentioning

confidence: 99%